Coenzyme_A

Coenzyme_A

SCHEMBL88057

CC(C)(COP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1OP(=O)(O)O)[C@@H](O)C(=O)NCCC(=O)NCCS.CCCCCCCCCCCC(O)O

nearest known ligand 0.88

Full drug profile on Sugi Atlas →

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
EP300 Q09472 4/20 0.88
AURKA O14965 2/20 0.88
CHAT P28329 2/20 0.88
NAA50 Q9GZZ1 2/20 0.88
KAT5 Q92993 2/20 0.88
KAT2B Q92831 1/20 0.88
CREBBP Q92793 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Coenzyme_A SCHEMBL16974425 0.95 EP300 (0.88) EP300AURKACHATNAA50KAT5
Coenzyme_A SCHEMBL2831401 0.95 EP300 (0.88) EP300AURKACHATNAA50KAT5
Coenzyme_A SCHEMBL2833078 0.95 EP300 (0.88) EP300AURKACHATNAA50KAT5
Coenzyme_A SCHEMBL2833005 0.95 EP300 (0.88) EP300AURKACHATNAA50KAT5
Coenzyme_A SCHEMBL16974417 0.94 EP300 (0.87) EP300AURKACHATNAA50KAT5
Coenzyme_A SCHEMBL15969462 0.94 EP300 (0.89) EP300AURKACHATNAA50KAT5
SCHEMBL16216009 0.94 EP300 (0.86) EP300AURKACHATNAA50KAT5
SCHEMBL16216000 0.94 EP300 (0.86) EP300AURKACHATNAA50KAT5
Coenzyme_A SCHEMBL13500623 0.94 EP300 (1.00) EP300AURKACHATNAA50KAT5
Coenzyme_A SCHEMBL26753 0.94 EP300 (1.00) EP300AURKACHATNAA50KAT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 253 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260103733-A1 METHODS AND ORGANISMS WITH INCREASED CARBON FLUX EFFICIENCIES AGAIN BIO APS (DK) 2026-04-16 US disclosed
US-20260028651-A1 METHOD OF PRODUCING & PROCESSING DIAMINES AGAIN BIO APS (DK) 2026-01-29 US disclosed
US-20250388910-A1 METHODS FOR ENHANCING MICROBIAL PRODUCTION OF SPECIFIC LENGTH FATTY ALCOHOLS IN THE PRESENCE OF METHANOL AGAIN BIO APS (DK) 2025-12-25 US disclosed
US-12503711-B2 Method of producing and processing diamines to a diamine free base using a carbonate intermediate and an engineered microorganism GENOMATICA, INC. (US) 2025-12-23 US disclosed
US-20250361531-A1 MICROORGANISMS AND METHODS FOR PRODUCTION OF 4-HYDROXYBUTYRATE, 1,4-BUTANEDIOL AND RELATED COMPOUNDS AGAIN BIO APS (DK) 2025-11-27 US disclosed
US-12435346-B2 Methods and organisms with increased carbon flux efficiencies GENOMATICA, INC. (US) 2025-10-07 US disclosed
US-12398396-B2 Methods for enhancing microbial production of specific length fatty alcohols in the presence of methanol GENOMATICA, INC. (US) 2025-08-26 US disclosed
US-12312627-B2 Microorganisms and methods for production of 4-hydroxybutyrate, 1,4-butanediol and related compounds GENOMATICA, INC. (US) 2025-05-27 US disclosed
EP-3074504-B1 METHODS FOR ENHANCING MICROBIAL PRODUCTION OF SPECIFIC LENGTH FATTY ALCOHOLS IN THE PRESENCE OF METHANOL GENOMATICA INC (US) 2024-12-25 EP disclosed
EP-4421181-A2 NON-NATURAL MICROBIAL ORGANISMS WITH IMPROVED ENERGETIC EFFICIENCY Genomatica, Inc. (US) 2024-08-28 EP disclosed
US-20110129904-A1 METHODS AND ORGANISMS FOR CONVERTING SYNTHESIS GAS OR OTHER GASEOUS CARBON SOURCES AND METHANOL TO 1,3-BUTANEDIOL GENOMATICA, INC. 2011-06-02 US disclosed
US-20110124911-A1 SEMI-SYNTHETIC TEREPHTHALIC ACID VIA MICROORGANISMS THAT PRODUCE MUCONIC ACID GENOMATICA, INC. 2011-05-26 US disclosed
WO-2011047101-A1 MICROORGANISMS FOR THE PRODUCTION OF 1,4-BUTANEDIOL, 4-HYDROXYBUTANAL, 4-HYDROXYBUTYRYL-COA, PUTRESCINE AND RELATED COMPOUNDS, AND METHODS RELATED THERETO GENOMATICA, INC. (US) 2011-04-21 WO disclosed
WO-2011031897-A1 MICROORGANISMS AND METHODS FOR THE CO-PRODUCTION OF ISOPROPANOL WITH PRIMARY ALCOHOLS, DIOLS AND ACIDS GENOMATICA, INC. (US) 2011-03-17 WO disclosed
WO-2011017560-A1 SEMI-SYNTHETIC TEREPHTHALIC ACID VIA MICROORGANISMS THAT PRODUCE MUCONIC ACID GENOMATICA, INC. (US) 2011-02-10 WO disclosed
US-20100323418-A1 ORGANISMS FOR THE PRODUCTION OF ISOPROPANOL, n-BUTANOL, AND ISOBUTANOL GENOMATICA, INC. (US) 2010-12-23 US disclosed
US-20100317069-A1 MICROORGANISMS AND METHODS FOR THE BIOSYNTHESIS OF ADIPATE, HEXAMETHYLENEDIAMINE AND 6-AMINOCAPROIC ACID AGAIN BIO APS (DK) 2010-12-16 US disclosed
US-20100304453-A1 MICROORGANISMS AND METHODS FOR CONVERSION OF SYNGAS AND OTHER CARBON SOURCES TO USEFUL PRODUCTS GENOMATICA, INC. (US) 2010-12-02 US disclosed
WO-2010129936-A1 MICROORGANISMS AND METHODS FOR THE BIOSYNTHESIS OF ADIPATE, HEXAMETHYLENEDIAMINE AND 6-AMINOCAPROIC ACID GENOMATICA, INC. (US) 2010-11-11 WO disclosed
WO-2010127303-A1 ORGANISMS FOR THE PRODUCTION OF ISOPROPANOL, N-BUTANOL, AND ISOBUTANOL GENOMATICA, INC. (US) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388910-A1 METHODS FOR ENHANCING MICROBIAL PRODUCTION OF SPECIFIC LENGTH FATTY ALCOHOLS IN THE PRESENCE OF METHANOL ADH5, ADH1C, ADH1A EP300 1466/4885AURKA 3847/4885CHAT 1999/4885
US-20260028651-A1 METHOD OF PRODUCING & PROCESSING DIAMINES DDC, DAO, ODC1 EP300 1948/4885AURKA 1208/4885CHAT 77/4885
US-20260103733-A1 METHODS AND ORGANISMS WITH INCREASED CARBON FLUX EFFICIENCIES PCK1, PC, PCK2 EP300 3357/4885AURKA 1528/4885CHAT 2024/4885
US-20250361531-A1 MICROORGANISMS AND METHODS FOR PRODUCTION OF 4-HYDROXYBUTYRATE, 1,4-BUTANEDIOL AND RELATED COMPOUNDS HSD17B10, HSD17B12, HADHB EP300 2217/4885AURKA 2812/4885CHAT 2185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.